Intellia Therapeutics Reports FDA Clearance to Resume MAGNITUDE Phase 3 Study in ATTR-CM Following Removal of Clinical Hold
Intellia Therapeutics has cleared a significant regulatory hurdle in its effort to advance CRISPR-based gene editing into late-stage cardiovascular medicine, announcing that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for the company’s MAGNITUDE Phase 3 clinical trial. The study is evaluating nexiguran ziclumeran (nex-z), an investigational in vivo CRISPR therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
The FDA’s decision enables Intellia to resume enrollment and dosing activities in MAGNITUDE, a pivotal late-stage trial designed to assess the safety and efficacy of a single-dose gene editing approach targeting the transthyretin (TTR) gene. The lifting of the hold follows the company’s implementation of additional risk mitigation measures and alignment with regulators regarding enhanced safety monitoring protocols.
Leadership Perspective and Strategic Focus
John Leonard, M.D., President and Chief Executive Officer of Intellia, described the development as an important step forward for the company’s ATTR program and broader gene editing ambitions. He emphasized that the regulatory alignment achieved with the FDA incorporates strengthened safety measures while preserving the opportunity to evaluate nex-z in a broad population of patients with ATTR-CM.
With the clinical hold now resolved for both MAGNITUDE and the related MAGNITUDE-2 Phase 3 trial in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), Intellia’s immediate focus shifts to completing patient enrollment across both programs. Leonard noted the company’s appreciation for the FDA’s responsiveness during the review process, as well as the ongoing commitment of investigators, study sites, and participating patients.
Background: Clinical Hold and Safety Signal
The FDA initially imposed clinical holds on the IND applications for both MAGNITUDE and MAGNITUDE-2 on October 29, 2025. The regulatory action followed the observation of Grade 4 liver transaminase elevations accompanied by increased total bilirubin levels in a patient dosed with nex-z in the MAGNITUDE trial. The event met protocol-defined pausing criteria, triggering regulatory scrutiny and suspension of further dosing.
Severe elevations in liver transaminases and bilirubin can signal potential drug-induced liver injury (DILI), a serious safety concern in clinical development, particularly for systemic therapies delivered via intravenous infusion. In the context of an in vivo gene editing therapy, any significant hepatic signal warrants careful evaluation given that the liver is a primary site of drug uptake and gene editing activity for TTR-targeted approaches.
Following the hold, Intellia worked closely with the FDA to investigate the event, review safety data across its program, and implement additional protective measures aimed at mitigating risk in future participants.
Enhanced Risk Mitigation Measures
As part of the agreed-upon path forward, Intellia has incorporated enhanced safety strategies into both MAGNITUDE and MAGNITUDE-2. These include:
- More frequent and intensified monitoring of liver laboratory parameters, particularly during the early post-dosing period.
- Clear guidance for short-term corticosteroid intervention in the event of elevated liver transaminases, intended to reduce inflammation and prevent progression of hepatic injury.
- Exclusion of patients with certain pre-existing liver abnormalities that could increase susceptibility to adverse hepatic events.
For the MAGNITUDE trial specifically, additional cardiovascular-related exclusion criteria have been introduced. These include excluding patients with a recent history of cardiovascular instability and those with a left ventricular ejection fraction below 25% at screening. Given the fragile health status of many ATTR-CM patients, these added safeguards aim to ensure a more stable baseline population for evaluation of the therapy’s safety profile.
Intellia has initiated discussions with clinical investigators, institutional review boards, ethics committees, and international regulatory authorities to resume trial activities in a coordinated and compliant manner.
Understanding ATTR-CM and ATTRv-PN
Transthyretin amyloidosis (ATTR) is a progressive and often fatal disease caused by the misfolding and aggregation of the transthyretin protein, leading to amyloid deposits in various tissues. In ATTR-CM, amyloid fibrils accumulate in the heart muscle, resulting in restrictive cardiomyopathy, heart failure, arrhythmias, and ultimately reduced survival.
In hereditary ATTR with polyneuropathy (ATTRv-PN), amyloid deposition primarily affects peripheral nerves, causing sensory loss, motor impairment, and autonomic dysfunction. Both forms of the disease stem from either mutant or wild-type TTR production by the liver.
Current standard-of-care therapies for ATTR focus largely on stabilizing the TTR protein or reducing its production through RNA-targeting approaches. However, these treatments typically require chronic administration. A one-time, potentially curative gene editing therapy represents a transformative shift in therapeutic strategy.
MAGNITUDE: A Pivotal Phase 3 Program in ATTR-CM
The MAGNITUDE trial is a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the efficacy and safety of nex-z in approximately 1,200 patients with ATTR-CM. The scale of the trial reflects both the seriousness of the disease and the need for robust clinical evidence to support potential regulatory approval.
Participants are randomized in a 2:1 ratio to receive a single 55 mg intravenous infusion of nex-z or placebo. The primary endpoint is a composite measure of cardiovascular-related events, including mortality. This endpoint aligns with regulatory expectations for heart failure and cardiomyopathy studies, where event-driven outcomes provide clinically meaningful evidence of benefit.
By targeting cardiovascular mortality and morbidity, the study seeks to demonstrate not only biomarker reduction but also tangible improvements in patient outcomes.
MAGNITUDE-2: Addressing Hereditary ATTR with Polyneuropathy
In parallel, the MAGNITUDE-2 Phase 3 trial is evaluating nex-z in approximately 60 patients with ATTRv-PN. This study is similarly randomized and double-blind, with patients receiving either a single 55 mg infusion of nex-z or placebo in a 1:1 ratio.
The primary endpoints focus on changes in the modified Neuropathy Impairment Score (mNIS) and serum TTR levels. Reduction of circulating TTR is considered a key mechanistic marker of therapeutic effect, while improvements in neuropathy scores provide functional clinical validation.
Although smaller in scale than MAGNITUDE, MAGNITUDE-2 addresses a genetically defined population with high unmet need, where disease progression can be relentless and debilitating.
Nex-z: A One-Time CRISPR-Based Therapy
Nexiguran ziclumeran (nex-z) is based on Nobel Prize-winning CRISPR/Cas9 gene editing technology. The therapy is designed to permanently inactivate the TTR gene in hepatocytes, thereby preventing production of the transthyretin protein responsible for amyloid formation.
Unlike RNA interference or antisense approaches that require ongoing dosing, nex-z aims to deliver a durable, potentially lifelong reduction in TTR after a single infusion. Interim Phase 1 data demonstrated deep, consistent, and sustained TTR reductions, supporting advancement into late-stage trials.
Regulatory agencies have recognized the potential significance of this approach. Nex-z has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, as well as Orphan Drug Designation from the European Commission. These designations are intended to facilitate development of therapies for rare diseases and expedite regulatory interactions.
Collaboration with Regeneron Pharmaceuticals
Development and commercialization of nex-z are being conducted under a multi-target collaboration between Intellia and Regeneron Pharmaceuticals. Under this partnership, Intellia leads development and commercialization efforts for the ATTR program, while leveraging Regeneron’s capabilities in biologics development, manufacturing, and global commercialization.
The collaboration structure reflects a broader trend in biotechnology, where smaller gene editing innovators partner with established biopharmaceutical companies to accelerate clinical development and expand global reach.
Broader Implications for In Vivo Gene Editing
The FDA’s decision to lift the clinical hold is notable not only for Intellia but also for the broader in vivo gene editing field. Systemic CRISPR therapies remain at the frontier of medicine, and regulatory scrutiny is correspondingly rigorous.
By resolving the hold through enhanced monitoring and targeted exclusion criteria, Intellia has demonstrated a path forward for managing safety risks in late-stage gene editing trials. The outcome reinforces that regulators are willing to support continued development when appropriate safeguards are implemented.
As Intellia resumes enrollment, the coming months will be critical. Successful completion of MAGNITUDE and MAGNITUDE-2 could position nex-z as the first one-time CRISPR-based therapy for ATTR amyloidosis, potentially redefining treatment paradigms for both cardiomyopathy and polyneuropathy forms of the disease.
Intellia Therapeutics is a clinical-stage biopharmaceutical company dedicated to leveraging CRISPR gene editing and related technologies to address severe and life-threatening diseases. The company’s mission centers on developing potentially curative therapies that address the root genetic causes of disease rather than managing symptoms chronically.
With deep expertise spanning gene editing science, lipid nanoparticle delivery, and clinical development, Intellia aims to establish a new standard of care across multiple therapeutic areas. The progress of nex-z in ATTR represents one of the most advanced applications of systemic CRISPR gene editing to date.
The lifting of the FDA clinical hold marks a renewed opportunity for Intellia to advance its late-stage program and further test whether a single-dose gene editing therapy can meaningfully alter the course of transthyretin amyloidosis. As enrollment resumes and data accumulate, the biotechnology and cardiovascular communities will be closely watching the evolution of this landmark program.
Source Link: https://ir.intelliatx.com/
